Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Dexcom (DXCM) over the last 15 years, with Q4 2025 value amounting to $3.1 million.

  • Dexcom's Gains from Investment Securities fell 8132.53% to $3.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.8 million, marking a year-over-year decrease of 7318.57%. This contributed to the annual value of $21.8 million for FY2025, which is 7318.57% down from last year.
  • According to the latest figures from Q4 2025, Dexcom's Gains from Investment Securities is $3.1 million, which was down 8132.53% from $6.0 million recorded in Q3 2025.
  • Over the past 5 years, Dexcom's Gains from Investment Securities peaked at $41.3 million during Q3 2024, and registered a low of -$25.9 million during Q2 2021.
  • Its 5-year average for Gains from Investment Securities is $5.4 million, with a median of $6.9 million in 2024.
  • As far as peak fluctuations go, Dexcom's Gains from Investment Securities crashed by 14915.25% in 2021, and later soared by 146923.08% in 2023.
  • Over the past 5 years, Dexcom's Gains from Investment Securities (Quarter) stood at -$13.1 million in 2021, then soared by 80.15% to -$2.6 million in 2022, then surged by 1469.23% to $35.6 million in 2023, then crashed by 53.37% to $16.6 million in 2024, then crashed by 81.33% to $3.1 million in 2025.
  • Its Gains from Investment Securities was $3.1 million in Q4 2025, compared to $6.0 million in Q3 2025 and $400000.0 in Q2 2025.